by Cora Novacut-Lee | Jul 12, 2024 | Article
A key mystery behind one of the most common autoimmune diseases may finally have an answer. For more information, please visit https://www.yahoo.com/news/scientists-identified-root-cause-lupus-173818604.html?guccounter=1 ...
by Ariana | Jun 27, 2024 | Article
We are pleased to announce that Belimumab (Benlysta), a prescription drug used to treat adults with lupus-related kidney inflammation (active lupus nephritis), has been included in the Exception Drug Status (EDS) Benefit of the Saskatchewan and Nova Scotia Formularies...
by Ariana | Jun 24, 2024 | Article
Dr. Boilard and his team have determined that an SLE-prone environment alters bioenergetic functions and gene expression in bone marrow megakaryocytes (MK). The data obtained from the Lupus Canada Catalyst grant project had significant impact on Dr. Boilard’s team to...
by admin | May 4, 2024 | Article
May 1, 2024 – Lupus Canada is pleased to share that Lupus Awareness Month is kicking off with a Saphnelo listing in Saskatchewan effective May 1st, 2024. With this listing, Saphnelo is now covered by 86% of Canadian public drug reimbursement plans. For more...
by admin | May 4, 2024 | Article
April 30, 2024 – Lupus Canada is pleased to share updates to the Benlysta listing in the following provinces: NL – Criteria-Apr-2024.pdf (gov.nl.ca) AB – Full April 1, 2024 – Alberta Drug Benefit List (bluecross.ca) NIHB...
